行情

CTIC

CTIC

CTi Biopharma
NASDAQ

实时行情|Nasdaq Last Sale

1.210
+0.221
+22.36%
盘后: 1.250 +0.04 +3.31% 18:51 12/11 EST
开盘
0.9900
昨收
0.9889
最高
1.350
最低
0.9561
成交量
291.95万
成交额
--
52周最高
1.590
52周最低
0.6001
市值
7,015.43万
市盈率(TTM)
-2.2638
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CTIC 新闻

  • CTI BioPharma Highlights Presentation Of Data Supporting Pacritinib's Benefit In Myelofibrosis Patients With Severe Thrombocytopenia At ASH
  • Benzinga.2天前
  • CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting
  • PR Newswire.2天前
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.4天前
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.4天前

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CTIC 简况

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
展开

Webull提供CTI BioPharma Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。